Company intelligence / Profile preview

Rege Nephro Co., Ltd.

Kyoto-shi/Sakyo-ku, Kyoto, Japanregenephro.co.jp ↗

Ownership: Private
Development stage: Phase 2

Overview

Rege Nephro is a clinical-stage biotech company developing therapies for kidney diseases, notably ADPKD and CKD. Its lead program, RN-014 (tamibarotene), a RAR agonist, is in Phase 2 trials in Japan with preliminary efficacy and no significant safety concerns reported. The company also develops an iPSC-derived nephron progenitor cell therapy for CKD, which has shown efficacy in animal models and is advancing toward clinical trials[7][8].

Therapeutic areas: Nephrology
Modalities: Small moleculesCell therapy
Industry: Biotech

Drug pipeline

1 asset

RN-032

Unknown

Partnerships

NIKKISO CO., LTD. – scale-up manufacturing collaboration[2]Mitsui Chemicals, Inc. – strategic investor and collaborator[6]Fujifilm – collaborative research on human kidney chip technology[10]

Beyond the preview

Go deeper on Rege Nephro Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rege Nephro Co., Ltd..

Explore the full profile